Medexus Pharmaceuticals Inc. MEDXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -424.93% | -393.55% | -206.54% | -107.64% | -83.40% |
| Total Depreciation and Amortization | 7.33% | 18.64% | 35.61% | 56.91% | 53.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.81% | 8.12% | -24.79% | -68.46% | -44.00% |
| Change in Net Operating Assets | -18.70% | -109.75% | -15.44% | 32.92% | -61.91% |
| Cash from Operations | 0.33% | -28.00% | -21.47% | -25.69% | -26.82% |
| Capital Expenditure | 69.92% | 81.52% | 15.85% | -54.55% | -228.00% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | 36.53% | 6.97% | 11.39% | -179.75% | -48.87% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -470.19% | -187.53% | -489.85% | -171.84% | 6.37% |
| Cash from Investing | -165.65% | -122.85% | -190.00% | -156.59% | -13.74% |
| Total Debt Issued | -- | -- | -- | 45.45% | -- |
| Total Debt Repaid | -8.04% | 0.08% | -190.69% | -206.53% | 52.77% |
| Issuance of Common Stock | -97.44% | -97.44% | -97.44% | -- | -23.37% |
| Repurchase of Common Stock | -- | -- | -- | 97.87% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 47.52% | 54.63% | 51.36% | 47.94% | 33.78% |
| Cash from Financing | 101.53% | 94.50% | -2,477.01% | 102.28% | 75.25% |
| Foreign Exchange rate Adjustments | 41.44% | -394.12% | 100.00% | 171.90% | -317.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -142.69% | -554.21% | -193.23% | 2,765.79% | 119.22% |